SCHEMBL7043185

SCHEMBL7043185

COc1nn(-c2ccc(N3CCCC3=O)c(C)c2)c(=O)o1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABHD16A O95870 2/20 0.49
MGLL Q99685 4/20 0.46
FAAH O00519 2/20 0.46
HSD17B10 Q99714 1/20 0.42
CRHR1 P34998 1/20 0.41
PDE10A Q9Y233 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
AKR1C3 P42330 1/20 0.39
TP53 P04637 2/20 0.39
LPL P06858 1/20 0.39
LIPC P11150 1/20 0.39
LIPE Q05469 1/20 0.39
LMNA P02545 1/20 0.38
BRD9 Q9H8M2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2191827 0.73 CRHR1 (0.57) HSD17B10CRHR1KDM4EKMT2AAKR1C3
SCHEMBL7046511 0.72 ABHD16A (0.57) ABHD16AMGLLFAAHLPLLIPC
SCHEMBL7044057 0.72 ABHD16A (0.49) ABHD16AMGLLFAAHKDM4EALDH1A1
SCHEMBL4404667 0.72 ABHD16A (0.59) ABHD16AMGLLFAAHHSD17B10ALDH1A1
Hydrochloric Acid SCHEMBL5425491 0.71 ABHD16A (0.58) ABHD16AMGLLFAAHHSD17B10ALDH1A1
SCHEMBL7656177 0.71 MGLL (0.61) ABHD16AMGLLFAAHLPLLIPC
SCHEMBL6601668 0.71 ABHD16A (0.54) ABHD16AMGLLFAAHLPLLIPC
SCHEMBL7048013 0.71 ABHD16A (0.65) ABHD16AMGLLFAAHKDM4EALDH1A1
SCHEMBL7571649 0.70 MGLL (0.72) ABHD16AMGLLFAAHKDM4EALDH1A1
SCHEMBL2760313 0.69 HSD17B10 (0.57) HSD17B10KDM4EALDH1A1KMT2AAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 ABHD16A 1922/4885MGLL 1542/4885FAAH 46/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE ABHD16A 62/4885MGLL 10/4885FAAH 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.